← boardnext 2028-06
IMRX
Immuneering Corporationdistress 3/10 · well-funded / low risk$4.33-3%today-53% from 52w high
Oncology 2
Lead: first-line pancreatic cancer · target PD-1 · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$81M
Runway
1.6 yrs
Shares 1y
—
Price & events
-19.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-9.5%
1W
-4.7%
1M
-29.4%
3M
-19.3%
6M
+5.5%
1Y
+263.4%
2Y
—
5Y
-75.4%
All
Overview
- Market Cap
- $112.18M
- Volume
- 78.08K
- 52 Week Range
- $3.04 – $9.26
- Total Shares
- 25.94M
- Float Shares
- 49.21M
- Short %
- 30.61%
- % Held by Insiders
- 13.48%
- % Held by Institutions
- 47.72%
- RVOL
- 0.06x
- Beta
- 0.41
Pipeline stages · 3 programs
Atebimetinib, GnP, mGnP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E)PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMM-6-415
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Atebimetinib, GnP, mGnP | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma | — | recruiting |
| 2026-06 | Phase 1/2 | IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E) | Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC) | 209 | active not recruiting |
| 2025-04-30 | Phase 1/2 | IMM-6-415 | Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous) | 30 | completed |
Catalyst news & presentations · 15
- mid-2028Guided 55%readoutPhase 3atebimetinib · Topline data readout from MAPKeeper 301 trialSEC 8-K
- late-2027Guided 70%readoutatebimetinib · Preliminary data readout from combo with LibtayoSEC 8-K
- mid-2027Guided 55%trial initiationsecondaryatebimetinib · Beginning IND-enabling studies for next Deep Cyclic Inhibition programSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3atebimetinib · Initiate pivotal trial in first-line pancreatic cancerSEC 8-K
- fourth quarter of 2026Guided 70%conferencedata presentationsecondaryatebimetinib · Additional preclinical data for combination with anti-PD-1SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026trial initiationsecondaryPhase 3atebimetinib · Dose first patient in pivotal Phase 3 clinical trial of atebimetinib in combination with mGnPSEC 8-K
- first half of 2026readoutPhase 1/2atebimetinib · Announce further updated survival data from over 50 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in ongoing Phase 1/2a clinical trialSEC 8-K
- mid-2026trial initiationsecondaryPhase 3atebimetinib · First patient dosed in pivotal Phase 3 MAPKeeper 301 trialSEC 8-K
- 2026-06-01safety signalatebimetinib · No Grade 5 TEAEs, no new safety signalsSEC 8-K
- fourth quarter of 2025readoutPhase 2atebimetinib · Additional data from Phase 2a portionSEC 8-K
- 2025trial initiationsecondaryPhase 2IMM-1-104 · Initiate Phase 2a arms of IMM-1-104 in combination with BRAF inhibitor and checkpoint inhibitorsSEC 8-K
- 2025-09-24partnershipatebimetinib · Entered into $25 million private placement with Sanofi subsidiary, contingent on $75 million public offeringSEC 8-K
- second quarter of 2025readoutPhase 2IMM-1-104 · Additional data from Phase 2a portion of IMM-1-104 trialSEC 8-K
- by year endconferencedata presentationsecondaryPhase 2IMM-1-104 · Initial data from at least one additional arm of the Phase 2a portion of the IMM-1-104 trial expected.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+313% upside) · 7 analysts
- 2026-07-20NeedhamBuy
- 2026-07-08Cantor FitzgeraldOverweight
- 2026-05-19Chardan CapitalBuy
- 2026-03-09NeedhamBuy
- 2025-11-13Chardan CapitalBuy
- 2025-10-31Leerink PartnersOutperform
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-21Publication in Cancer Research Details Atebimetinib’s - GlobeNewswire
- 2026-07-20IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
- 2026-07-19Immuneering (IMRX) upgraded to buy: Here's what you should know - MSN
- 2026-07-18Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17IMRX News | IMMUNEERING CORP - CLASS A (NASDAQ:IMRX) - ChartMill
- 2026-07-17Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
- 2026-07-17Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
- 2026-07-17Immuneering Corporation Announces Grants of Inducement Awards - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.